Date: 2012-02-08
Type of information:
Product name: NRP-1 small molecule antagonists
Compound: NRP-1 small molecule antagonists
Therapeutic area:
Action mechanism: Ark has developed the first drug-like small molecule antagonists of VEGF binding to NRP-1 which, in pre-clinical in vivo studies, show inhibition of both tumour growth and the development of the tumour blood supply (anti-angiogenic) as well as directly impairing tumour cell growth and migration.
Company: Ark Therapeutics (UK)
Disease: cancers
Latest news: * On February 8, 2012, Ark Therapeutics announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance in respect of a patent covering the structures of candidate compounds in Ark\'s Neuropilin-1 receptor (\"NRP-1\") small molecule antagonist programme. Formal grant of this patent is expected in two months.
Patents:
Submission of marketing authorization application USA :
Submission of marketing authorization application UE:
Withdrawal of marketing authorization application USA:
Withdrawal of marketing authorization application UE:
US authorization:
UE authorization:
Favourable opinion UE:
Favourable opinion USA:
Orphan status USA:
Orphan status UE:
Pediatric exclusivit _USA:
Pediatric exclusivity UE: OTC status: Other news:
